Compare WST & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WST | RVMD |
|---|---|---|
| Founded | 1923 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6B | 30.1B |
| IPO Year | 2004 | N/A |
| Metric | WST | RVMD |
|---|---|---|
| Price | $331.30 | $189.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 19 |
| Target Price | ★ $325.86 | $140.84 |
| AVG Volume (30 Days) | 726.5K | ★ 2.1M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.30% | N/A |
| EPS Growth | ★ 1.49 | N/A |
| EPS | ★ 4.07 | N/A |
| Revenue | ★ $2,886,900,000.00 | N/A |
| Revenue This Year | $6.76 | N/A |
| Revenue Next Year | $6.22 | $533.02 |
| P/E Ratio | $81.39 | ★ N/A |
| Revenue Growth | ★ 1.95 | N/A |
| 52 Week Low | $223.83 | $34.00 |
| 52 Week High | $386.00 | $194.56 |
| Indicator | WST | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 60.66 |
| Support Level | $321.94 | $176.00 |
| Resistance Level | $336.82 | $193.83 |
| Average True Range (ATR) | 11.14 | 6.99 |
| MACD | -4.53 | -1.05 |
| Stochastic Oscillator | 8.30 | 65.41 |
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.